Epidermolysis bullosa – Cannabis Research

Epidermolysis bullosa Research Dashboard

4

Primary Studies

4

Related Studies

8

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

4

Meta-analyses/Reviews

0

Animal studies

0

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 8 studies associated with Epidermolysis bullosa.

Here is a small sampling of Epidermolysis bullosa studies by title:


Components of the Epidermolysis bullosa Research Dashboard

  • Dosing information available for Epidermolysis bullosa
  • Chemotype guidance for treating Epidermolysis bullosa with cannabis
  • Synopsis of cannabis research for Epidermolysis bullosa
  • Individual study details for Epidermolysis bullosa

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Epidermolysis bullosa

Description of Epidermolysis bullosa

Epidermolysis bullosa (EB) is an inherited non-inflammatory skin condition that is characterized by overly sensitive skin and mucosa (the inner lining of body cavities and certain organs) that tend form fluid filled blisters that can break with even the slightest trauma. The onset of EB starts at birth and is caused by caused by mutations (in the genes encoding keratins 5 and 14, collagen vii or laminin 5). These skin traumas frequently lead to several common secondary complications such as slow or difficult would closure or healing, the formation of skin ulcers, chronic pains, itching, infections, the development of scar tissues, loss of bodily fluids, and loss of quality of life. Types of EB are classified by severity of blister formation such as EB simplex (EBS), junctional EB (JEB) and dystrophic EB (DEB), the latter of which is further discerned as recessive DEB (RDEB) and dominant DEB (DDEB). Key symptoms of pain and pruritis are poorly served by standard pharmaceutical regiments and as such novel treatment option are of significant interest to this patient population.

Disease Classification

Condition: Epidermolysis bullosa
Disease Family:
Organ System: Integumentary System
ICD-10 Chapter: Congenital malformations, deformations and chromosomal abnormalities
ICD-10 Code: Q81.9

Epidermolysis bullosa Symptoms:

Blister formation (fluid filled), difficult would closure or healing, the formation of skin ulcers, chronic pains, itching, infections, the development of scar tissues, loss of bodily fluids, loss of quality of life

Also known as:

Acquired EB, simple EB, EB simplex (EBS), junctional EB (JEB) and dystrophic EB (DEB), the latter of which is further discerned as recessive DEB (RDEB) and dominant DEB (DDEB).

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.